Platelet glycoprotein IIIa Leu33Pro gene polymorphism and coronary artery disease: A meta-analysis of cohort studies

References

• De Luca G, Suryapranata H, Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: An overview of current status. Prog Cardiovasc Dis 2008;50:352–382
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kubica J, Castriota F, Gibson CM, De Luca G, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: Evidence from a meta-analysis of randomised trials. EuroIntervention 2011;7:985–994
   PubMedGoogle Scholar
• De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, DE Carlo M, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: Individual patient's data meta-analysis. J Thromb Haemost 2011;9:2361–2370
   PubMed Web of Science ®Google Scholar
• De Luca G, Schaffer A, Wirianta J, Suryapranata H. Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI. Int J Cardiol 2013;168:2070–2081
   PubMed Web of Science ®Google Scholar
• De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials. Atherosclerosis 2012;222:426–433
   PubMed Web of Science ®Google Scholar
• De Luca G, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analysis of randomised trials. Thromb Haemost 2009;102:428–436
   PubMed Web of Science ®Google Scholar
• De Luca G, Marino P. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J 2007;154:1085.e1–1085.e6
   PubMedGoogle Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: The evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012;14:1–10
   PubMed Web of Science ®Google Scholar
• De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009;207:181–185
   PubMed Web of Science ®Google Scholar
• De Luca G, Ernst N, van ‘t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J 2006;151:1256–1259
   PubMed Web of Science ®Google Scholar
• De Luca G, Maas AC, Suryapranata H, et al. Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Am Heart J 2005;150:1248–1254
   PubMed Web of Science ®Google Scholar
• Incalcaterra E, Accardi G, Balistreri CR, et al. Pro-inflammatory genetic markers of atherosclerosis. Curr Atheroscler Rep 2013;15:329
   PubMedGoogle Scholar
• Newmann PJ, Derbes RS, Aster RH. The human platelet alloantigens PlA1 and PlA2 are associated with a leucine 33/proline 33 Amino Acid Polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA Typing. J. Clin Invest 1989; 83:1778–1781
   PubMed Web of Science ®Google Scholar
• Nurden AT. Polymorphisms of human platelet membrane glycoproteins: Structure and clinical significance. Thromb Haemost 1995;74:345–351
   PubMed Web of Science ®Google Scholar
• Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090–1094
   PubMed Web of Science ®Google Scholar
• Walter D, Schachinger V, Elsner M, Dimmeler S, Zeiher A. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997;350:1217–1219
   PubMed Web of Science ®Google Scholar
• Lagercrantz J, Bergman M, Lundman P, Tornvall P, Hjemdahl P, Hamsten A, Eriksson P. No evidence that the PLA1/PLA2 polymorphism of platelet glycoprotein IIIa is implicated in angiographically characterized coronary atherosclerosis and premature myocardial infarction. Blood Coagul Fibrinolysis 2003;14:749–753
   PubMed Web of Science ®Google Scholar
• Scaglione L, Bergerone S, Gaschino G, Imazio M, Maccagni A, Gambino R, Cassader M, Di Leo M, Macchia G, Busca A, et al. Lack of relationship between the PlA1/PlA2 polymorphism of platelet glycoprotein IIIa and premature myocardial infacrtion. Eur J Clin Invest 1998;28:385–388
   PubMed Web of Science ®Google Scholar
• Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: A meta-analysis. Thromb Haemost 2001;85:626–633
   PubMed Web of Science ®Google Scholar
• Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006;367:651–658
   PubMed Web of Science ®Google Scholar
• Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013;13:154
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med 2009;151:W65–W94
   PubMed Web of Science ®Google Scholar
• Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, Carlquist JF. Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. J Am Coll Cardiol 1999;33:727–733
   PubMed Web of Science ®Google Scholar
• Zotz RB, Winkelmann BR, Nauck M, Giers G, Maruhn-Debowski B, März W, Scharf RE. Polymorphism of platelet membrane glycoprotein IIIa: Human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998;79:731–735
   PubMed Web of Science ®Google Scholar
• Carter AM, Ossei-Gerning N, Grant PJ. Platelet glycoprotein IIIa PlA polymorphism in young men with myocardial infarction. Lancet 1996;348:485–486
   PubMed Web of Science ®Google Scholar
• Böttiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schömig K, von Beckerath N, Schömig A. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000;83:559–562
   PubMed Web of Science ®Google Scholar
• Gardemann A, Humme J, Stricker J, Nguyen QD, Katz N, Philipp M, Tillmanns H, Hehrlein FW, Rau M, Haberbosch W. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost 1998;80:214–217
   PubMed Web of Science ®Google Scholar
• Aydinalp A, Atar I, Atac FB, Yazici AC, Cicek M, Yilmaz M, Ozgul A, Atar A, Korkmaz ME, Ozin B, Muderrisoglu H. Glycoprotein IIIa gene polymorphism and coronary artery disease. Acta Cardiol 2010;65:225–230
   PubMed Web of Science ®Google Scholar
• Verdoia M, Cassetti E, Schaffer A, Barbieri L, Di Giovine G, Nardin M, Marino P, Sinigaglia F, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS). Relationship between glycoprotein IIIa platelet receptor gene polymorphism and coronary artery disease. Angiology 2014. [Epub ahead of print]
   Google Scholar
• De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, et al. Mean platelet volume and the extent of coronary artery disease: Results from a large prospective study. Atherosclerosis 2009;206:292–297
   PubMed Web of Science ®Google Scholar
• Verdoia M, Camaro C, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty. Atherosclerosis 2013;228:136–141
   PubMed Web of Science ®Google Scholar
• De Luca G, Verdoia M, Cassetti E, Schaffer A, Di Giovine G, Bertoni A, Di Vito C, Sampietro S, Aimaretti G, Bellomo G, et al.; Novara Atherosclerosis Study (NAS) Group. Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients. Blood Coagul Fibrinolysis 2013;24:619–624
   PubMed Web of Science ®Google Scholar
• De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, Schaffer A, Coppo L, Bellomo G, Marino P; Novara Atherosclerosis Study Group. Platelet distribution width and the extent of coronary artery disease: Results from a large prospective study. Platelets 2010;21:508–514
   PubMed Web of Science ®Google Scholar
• De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, Marino P; Novara Atherosclerosis Study Group (NAS). High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 2011;31:458–463
   PubMed Web of Science ®Google Scholar
• De Luca G, Secco GG, Santagostino M, Venegoni L, Iorio S, Cassetti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P; Novara Atherosclerosis Study Group (NAS). Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012;22:426–433
   PubMed Web of Science ®Google Scholar
• Tantry US, Jeong YH, Navarese EP, Kubica J, Gurbel PA. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Rev Cardiovasc Ther 2013;11:447–462
   PubMedGoogle Scholar
• Verdoia M, Secco GG, Cassetti E, Schaffer A, Barbieri L, Perrone-Filardi P, Marino P, Suryapranata H, Sinigaglia F, De Luca G. Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty. Blood Coagul Fibrinolysis 2014;25:107–113
   PubMed Web of Science ®Google Scholar
• Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). MTHFR polymorphism and risk of periprocedural myocardial infarction after coronary stenting. Nutr Metab Cardiovasc Dis Nutr Metab Cardiovasc Dis 2014;24:532--537
   Google Scholar
• Loncar R, Stoldt V, Hellmig S, Zotz RB, Mihalj M, Scharf RE. HPA-1 polymorphism of alphaIIbbeta3 modulates platelet adhesion onto immobilized fibrinogen in an in-vitro flow system. Thromb J 2007;5:12
   PubMedGoogle Scholar
• Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, Fox KM. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999;20:742–747
   PubMed Web of Science ®Google Scholar
• Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007;119:355–360
   PubMed Web of Science ®Google Scholar
• Garcia-Ribes M, Gonzalez-Lamuño D, Hernandez-Estefania R, Colman T, Pocovi M, Delgado-Rodriguez M, Garcia-Fuentes M, Revuelta JM. Polymorphism of the platelet glycoprotein IIIa gene in patients with coronary stenosis. Thromb Haemost 1998;79:1126–1129
   PubMed Web of Science ®Google Scholar
• Mikkelsson J, Perola M, Laippala P, Savolainen V, Pajarinen J, Lalu K, Penttilä A, Karhunen PJ. Glycoprotein IIIa Pl(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999;19:2573–2578
   PubMed Web of Science ®Google Scholar
• Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med 2003;22:1741–1760
   PubMed Web of Science ®Google Scholar
• Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009;41:334–341
   PubMed Web of Science ®Google Scholar
• Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Böttiger C, Mehilli J, Schömig K, von Beckerath N. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005–1010
   PubMed Web of Science ®Google Scholar
• Galasso G, Santulli G, Piscione F, De Rosa R, Trimarco V, Piccolo R, Cassese S, Iaccarino G, Trimarco B, Chiariello M. The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events. BMC Cardiovasc Disord 2010;10:41
   PubMed Web of Science ®Google Scholar